Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib

Asian J Surg. 2023 Nov;46(11):5246-5247. doi: 10.1016/j.asjsur.2023.07.008. Epub 2023 Jul 19.
No abstract available

Keywords: PD-1; anti-angiogenic agent; apatinib; camrelizumab; combination therapy; sarcomatous choledochal carcinoma.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma*
  • Humans
  • Neoplasm Recurrence, Local
  • Sarcoma*

Substances

  • apatinib
  • camrelizumab
  • Antibodies, Monoclonal, Humanized